Skip to main content
Fig. 5 | BMC Biology

Fig. 5

From: A gossypol derivative effectively protects against Zika and dengue virus infection without toxicity

Fig. 5

Ability of gossypol derivative ST087010 to inhibit binding of ZIKV EDIII to EDIII-specific neutralizing mAbs, as well as ZIKV NS2B-NS3 protease activity. A–D Percent inhibition (% inhibition) of EDIII-mAb binding was calculated in the presence or absence of serially diluted compounds (ST087010 or gossypol control) based on the ELISA result. Four ZIKV EDIII-specific mAbs were used for testing, and IC50 values were calculated. ZIKV EDI/DII-specific mAb ZKA78 (E) and DMSO were used as controls. F Ability of ST087010 in inhibition of ZIKV NS2B-NS3 protease activity. Percent inhibition (% inhibition) of protease activity was measured in the presence or absence of serially diluted compounds, and IC50 values were calculated. The data are expressed as the mean ± s.e.m of 4 wells. The experiments were repeated twice with similar results

Back to article page